42.78
+0.55(+1.30%)
Currency In USD
| Previous Close | 42.23 |
| Open | 42.5 |
| Day High | 42.85 |
| Day Low | 42.22 |
| 52-Week High | 42.79 |
| 52-Week Low | 16.54 |
| Volume | 51,883 |
| Average Volume | 477,898 |
| Market Cap | 1.22B |
| PE | -26.25 |
| EPS | -1.63 |
| Moving Average 50 Days | 36.33 |
| Moving Average 200 Days | 29.47 |
| Change | 0.55 |
If you invested $1000 in LENZ Therapeutics, Inc. (LENZ) since IPO date, it would be worth $2,640.74 as of September 18, 2025 at a share price of $42.78. Whereas If you bought $1000 worth of LENZ Therapeutics, Inc. (LENZ) shares 6 months ago, it would be worth $1,753.28 as of September 18, 2025 at a share price of $42.78.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
LENZ Therapeutics to Present at Upcoming Investor and Medical Conferences
GlobeNewswire Inc.
Aug 25, 2025 12:00 PM GMT
SAN DIEGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ™ (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-ap
LENZ Therapeutics Announces US FDA Approval of VIZZ™ for the Treatment of Presbyopia
GlobeNewswire Inc.
Jul 31, 2025 8:05 PM GMT
VIZZ is the first and only aceclidine-based eye drop approved to improve near vision in adults with presbyopia, a condition impacting approximately 128 million adults in the United States First once daily solution to treat blurry near vision with pro
LENZ Therapeutics Announces NMPA Submission of New Drug Application for LNZ100 in China for the Treatment of Presbyopia
GlobeNewswire Inc.
Jul 28, 2025 12:00 PM GMT
Submission of NDA for LNZ100 in China by CORXEL Pharmaceuticals results in achievement of first milestone due to LENZ under the Development and Commercialization Agreement SAN DIEGO, July 28, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq